FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945442954> ?p ?o ?g. }

• W2945442954 endingPage "686" @default.
• W2945442954 startingPage "680" @default.
• W2945442954 abstract "Background: A growing number of studies have shown that thiazolidinediones (TZD) can be antipsoriatic. Pioglitazone is a representative of the class of antidiabetic drugs known as TZD. TZD can activate nuclear peroxisome proliferator-activated receptors (PPAR)-c. PPARs are expressed on epidermal keratinocytes and exert their effects by promoting the terminal differentiation of keratinocytes, inhibiting epidermal growth, and reducing inflammatory responses. These observations suggest that TZD have potential benefits in the treatment of cutaneous and metabolic pathologies associated with psoriasis.Objective: A systematic review and meta-analysis was carried out to evaluate the efficacy of combined pioglitazone treatment. We point out three controversial side effects from administration of pioglitazone in psoriasis: elevated liver enzymes, weight gain, and nausea.Study selection: Randomized, single blind, or double blind, published studies of pioglitazone compared with placebo given to patients with plaque psoriasis for 10 weeks or 12 weeks were considered for inclusion in this review. The primary outcomes were 75% or greater improvement in the Psoriasis Area and Severity Index score from baseline (PASI 75) with pioglitazone.Data collection and analysis: The systematic literature search was conducted in the PubMed, Embase, Google Scholar, and Cochrane databases from inception up to December 20 2018. Data analysis was done using Revman 5.3 Haymarket, London, United Kingdom.Main results: We included six studies (three publications of pioglitazone only; three publications of pioglitazone combination therapy) comprising a total of 294 patients (n = 149 with pioglitazone only and n = 145 with pioglitazone combination therapy) in the analysis. There was a significant PASI 75 response, in the pioglitazone only subgroup as compared to placebo (OR = 8.74, 95% CI 3.76–20.31, p < .00001), and the pioglitazone combination subgroup as compared to placebo (OR = 4.64, 95% CI 2.03–10.60, p < .00001), others, the total of pioglitazone as compared to placebo (OR = 6.37, 95% CI 3.55–11.43, p < .00001), and tests of subgroup differences show: p = .29, I2 = 9.5%. The incidence rate of elevated liver enzymes (OR = 3.70, 95% CI 0.56–24.31, p = .99), weight gain (OR = 1.44, 95% CI 0.60–3.47, p = .41), and nausea (OR = 0.76, 95% CI 0.23–2.49, p = .65) were not significantly different compared with the control group.Conclusion: Pioglitazone has efficacy for the treatment of plaque psoriasis. There is no significant difference between patients treated with pioglitazone only or in combination with other therapies. The incidence rate of side effects associated with pioglitazone treatment such as elevated liver enzymes, weight gain, and nausea were not significantly different compared with the control group." @default.
• W2945442954 created "2019-05-29" @default.
• W2945442954 creator A5018244700 @default.
• W2945442954 creator A5022216767 @default.
• W2945442954 creator A5040519903 @default.
• W2945442954 creator A5053571071 @default.
• W2945442954 creator A5080700370 @default.
• W2945442954 date "2019-08-02" @default.
• W2945442954 modified "2023-10-01" @default.
• W2945442954 title "Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials" @default.
• W2945442954 cites W1922106411 @default.
• W2945442954 cites W1932483587 @default.
• W2945442954 cites W1969272959 @default.
• W2945442954 cites W1989619519 @default.
• W2945442954 cites W1996656260 @default.
• W2945442954 cites W2006340844 @default.
• W2945442954 cites W2032434473 @default.
• W2945442954 cites W2032466268 @default.
• W2945442954 cites W2037862910 @default.
• W2945442954 cites W2046429755 @default.
• W2945442954 cites W2073501077 @default.
• W2945442954 cites W2083441501 @default.
• W2945442954 cites W2116110268 @default.
• W2945442954 cites W2121243509 @default.
• W2945442954 cites W2131430597 @default.
• W2945442954 cites W2151354147 @default.
• W2945442954 cites W2152262899 @default.
• W2945442954 cites W2158969881 @default.
• W2945442954 cites W2170191278 @default.
• W2945442954 cites W2508714726 @default.
• W2945442954 cites W2563819357 @default.
• W2945442954 cites W2590510978 @default.
• W2945442954 cites W2899011411 @default.
• W2945442954 doi "https://doi.org/10.1080/09546634.2019.1610552" @default.
• W2945442954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31116619" @default.
• W2945442954 hasPublicationYear "2019" @default.
• W2945442954 type Work @default.
• W2945442954 sameAs 2945442954 @default.
• W2945442954 citedByCount "15" @default.
• W2945442954 countsByYear W29454429542019 @default.
• W2945442954 countsByYear W29454429542020 @default.
• W2945442954 countsByYear W29454429542021 @default.
• W2945442954 countsByYear W29454429542022 @default.
• W2945442954 countsByYear W29454429542023 @default.
• W2945442954 crossrefType "journal-article" @default.
• W2945442954 hasAuthorship W2945442954A5018244700 @default.
• W2945442954 hasAuthorship W2945442954A5022216767 @default.
• W2945442954 hasAuthorship W2945442954A5040519903 @default.
• W2945442954 hasAuthorship W2945442954A5053571071 @default.
• W2945442954 hasAuthorship W2945442954A5080700370 @default.
• W2945442954 hasConcept C126322002 @default.
• W2945442954 hasConcept C134018914 @default.
• W2945442954 hasConcept C142724271 @default.
• W2945442954 hasConcept C16005928 @default.
• W2945442954 hasConcept C168563851 @default.
• W2945442954 hasConcept C204787440 @default.
• W2945442954 hasConcept C27081682 @default.
• W2945442954 hasConcept C2777011040 @default.
• W2945442954 hasConcept C2777180221 @default.
• W2945442954 hasConcept C2778384471 @default.
• W2945442954 hasConcept C2780564577 @default.
• W2945442954 hasConcept C555293320 @default.
• W2945442954 hasConcept C71924100 @default.
• W2945442954 hasConcept C95190672 @default.
• W2945442954 hasConcept C98274493 @default.
• W2945442954 hasConceptScore W2945442954C126322002 @default.
• W2945442954 hasConceptScore W2945442954C134018914 @default.
• W2945442954 hasConceptScore W2945442954C142724271 @default.
• W2945442954 hasConceptScore W2945442954C16005928 @default.
• W2945442954 hasConceptScore W2945442954C168563851 @default.
• W2945442954 hasConceptScore W2945442954C204787440 @default.
• W2945442954 hasConceptScore W2945442954C27081682 @default.
• W2945442954 hasConceptScore W2945442954C2777011040 @default.
• W2945442954 hasConceptScore W2945442954C2777180221 @default.
• W2945442954 hasConceptScore W2945442954C2778384471 @default.
• W2945442954 hasConceptScore W2945442954C2780564577 @default.
• W2945442954 hasConceptScore W2945442954C555293320 @default.
• W2945442954 hasConceptScore W2945442954C71924100 @default.
• W2945442954 hasConceptScore W2945442954C95190672 @default.
• W2945442954 hasConceptScore W2945442954C98274493 @default.
• W2945442954 hasIssue "7" @default.
• W2945442954 hasLocation W29454429541 @default.
• W2945442954 hasLocation W29454429542 @default.
• W2945442954 hasOpenAccess W2945442954 @default.
• W2945442954 hasPrimaryLocation W29454429541 @default.
• W2945442954 hasRelatedWork W1568338448 @default.
• W2945442954 hasRelatedWork W187890988 @default.
• W2945442954 hasRelatedWork W2046429755 @default.
• W2945442954 hasRelatedWork W2054748203 @default.
• W2945442954 hasRelatedWork W2073564793 @default.
• W2945442954 hasRelatedWork W2560620037 @default.
• W2945442954 hasRelatedWork W3084176453 @default.
• W2945442954 hasRelatedWork W3164257059 @default.
• W2945442954 hasRelatedWork W3176220181 @default.
• W2945442954 hasRelatedWork W4312083527 @default.
• W2945442954 hasVolume "31" @default.
• W2945442954 isParatext "false" @default.
• W2945442954 isRetracted "false" @default.

• next